NCT03571633 - Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 6, 2018

Primary Completion Date

January 31, 2025

Study Completion Date

September 30, 2025

Conditions

HER2-positive Breast CancerOperable Breast Cancer

Interventions

DRUG

Trastuzumab + Paclitaxel

During neoadjuvant period, weekly paclitaxel + trastuzumab (every 3 weeks, Q3W) During adjuvant period, weekly trastuzumab (every 3 weeks, Q3W)

DRUG

Pegfilgrastim

During neoadjuvant period, weekly pegfilgrastim (every 3 weeks, Q3W)

Trial Locations (9)

RECRUITING

CHRU Besançon, Besançon

RECRUITING

Groupe Hospitalier Mutualiste de Grenoble, Grenoble

RECRUITING

Centre de Lutte contre le Cancer Jean Perrin, Clermont-Ferrand

RECRUITING

Institut Sainte Catherine, Avignon

RECRUITING

Centre Leon Berard, Lyon

RECRUITING

Hopital Prive Jean Mermoz, Lyon

RECRUITING

Centre Hospitalier Annecy Genevois, Pringy

RECRUITING

Centre Hospitalier Universitaire de Saint Etienne, Saint-Etienne

RECRUITING

Clinique Charcot, Sainte-Foy-lès-Lyon